Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Obstetrics/Gynecology (Women’s Health) | Oncology
Search Medical Condition
Gestational Trophoblastic Neoplasia Clinical Trials
A listing of Gestational Trophoblastic Neoplasia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (5) clinical trials
GOG 0275: A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01535053?term=GOG+0275&rank=1
The French National Reference Centre of GTD
The French Gestational Trophoblastic Disease (GTD) centre has been set up and active by registering, monitoring and treating women with GTD since november 1999. The aim is to improve the management of trophoblastic disease in France. About 850 new cases are registered each year and 140 women treated, mostly with ...
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
TRC105 is a monoclonal antibody that binds to endoglin, an angiogenic target highly expressed on the tumor vessels and tumor cells in gestational trophoblastic neoplasia (GTN). Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) that inhibits angiogenesis and extends survival in patients with a wide variety of ...
Second Curettage in Treating Patients With Persistent Non-Metastatic Gestational Trophoblastic Tumor
OBJECTIVES: Primary - To determine the response to second curettage in patients with persistent, non-metastatic gestational trophoblastic neoplasia (GTN). Secondary - To evaluate if response to a second curettage is independent of the tumor burden as measured by the quantitative beta-human chorionic gonadotropin (hCG) assay at study entry. - To ...
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
PRIMARY OBJECTIVES: I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. SECONDARY OBJECTIVES: I. To evaluate toxicities in each cohort. II. To estimate overall survival (OS), progression-free ...
